Drug-induced immune hemolytic anemia

Definition

Drug-induced immune hemolytic anemia is a blood disorder that occurs when a medicine triggers the body's defense (immune) system to attack its own red blood cells. This causes red blood cells to break down earlier than normal, a process called hemolysis.

Alternative Names

Immune hemolytic anemia secondary to drugs; Anemia - immune hemolytic - secondary to drugs

Causes

Anemia is a condition in which the body does not have enough healthy red blood cells. Red blood cells provide oxygen to body tissues.

Normally, red blood cells last for about 120 days in the body. In people with hemolytic anemia, red blood cells in the blood are destroyed earlier than normal.

In some cases, a drug can cause the immune system to mistake your own red blood cells for foreign substances. The body responds by making antibodies to attack the body's own red blood cells. The antibodies attach to red blood cells and cause them to break down too early.

Drugs that can cause this type of hemolytic anemia include:

Drug-induced hemolytic anemia is rare in children.

Symptoms

Symptoms may include any of the following:

Exams and Tests

A physical exam may show an enlarged spleen. You may have blood and urine tests to help diagnose this condition.

Tests may include:

Treatment

Stopping the drug that is causing the problem may relieve or control the symptoms.

You may need to take a medicine called prednisone to suppress the immune response against the red blood cells. Special blood transfusions may be needed to treat severe symptoms.

Outlook (Prognosis)

The outcome is good for most people if they stop taking the drug that is causing the problem.

Possible Complications

Death caused by severe anemia is rare.

When to Contact a Medical Professional

See your health care provider if you have symptoms of this condition.

Prevention

Avoid the drug that caused this condition.

References

Brandow AM. Hemolytic anemias resulting from extracellular factors -- immune hemolytic anemias. In: Kliegman RM, St. Geme JW, Blum NJ, Shah SS, Tasker RC, Wilson KM, eds. Nelson Textbook of Pediatrics. 21st ed. Philadelphia, PA: Elsevier; 2020:chap 491.

Michel M. Autoimmune and intravascular hemolytic anemias. In: Goldman L, Schafer AI, eds. Goldman-Cecil Medicine. 26th ed. Philadelphia, PA: Elsevier; 2020:chap 151.



Review Date: 2/2/2023
Reviewed By: Mark Levin, MD, Hematologist and Oncologist, Monsey, NY. Review provided by VeriMed Healthcare Network. Also reviewed by David C. Dugdale, MD, Medical Director, Brenda Conaway, Editorial Director, and the A.D.A.M. Editorial team.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, timeliness, or correctness of any translations made by a third-party service of the information provided herein into any other language. © 1997- A.D.A.M., a business unit of Ebix, Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
© 1997- adam.comAll rights reserved.
A.D.A.M. content is best viewed in IE9 or above, Firefox and Google Chrome browser.